Presentation is loading. Please wait.

Presentation is loading. Please wait.

Cancer Drug Development in Industry:

Similar presentations


Presentation on theme: "Cancer Drug Development in Industry:"— Presentation transcript:

1 Cancer Drug Development in Industry:

2 Outline of my Talk Targeted Therapy for Cancer Challenges and Costs
Another Example: Hepatitis C Approval Times for New Cancer Drugs Combination is Key – What are the Costs? Future Directions

3 Outline of my Talk Targeted Therapy for Cancer Challenges and Costs
Another Example: Hepatitis C Approval Times for New Cancer Drugs Combination is Key – What are the Costs? Future Directions

4 Cancer in Europe 30% of all Europeans will come down with cancer during their lifes. 20% of all Europeans will die due to cancer. Cancer is the second most frequent cause of death in Europe. European Community (2013): - Cancer Morbidity: 1,500,000 pts. per year - Cancer Mortality: ,000 pts. per year

5 Cancer Treatment: Paradigm Shift
Chemotherapy, Radiotherapy, Surgery Targeted therapy Unspecific targets Specific targets Reduction of tumour mass Inhibition of tumour growth Survival

6 Do we know the optimal target?
Proliferation Metastasis Angiogenesis Apoptosis Shc Grb2 PI3-K Sos-1 Ras AKT Raf MEKK-1 MEK mTOR MKK-7 ERK JNK

7 Do we know the optimal target?
Shc Grb2 PI3-K Sos-1 Ras AKT Raf MEKK-1 MEK mTOR MKK-7 ERK JNK

8 Sos-1 Ras MEKK-1 MEK Shc PI3-K Raf MKK-7 Grb2 AKT JNK ERK

9 Where is the target? Sos-1 PI3-K Ras Grb2 Shc Raf MEK MEKK-1 JNK MKK-7
AKT JNK ERK

10 An Engineer’s Perspective…
EGF EGFR

11 Do we know the Optimal Target?
NO – plain and simple!

12 32 small molecules within 14 years!
2012 Axitinib Pazopanib Bosutinib Ponatinib Cabozantinib Regorafenib 2005/06 Sorafenib Sunitinib Dasatinib 2014 Ceritinib Ibrutinib Idelalisib 2009 Everolimus Pazopanib 2001 Imatinib 32 small molecules within 14 years! 2003/04 Erlotinib Gefitinib 2007 Lapatinib Nilotinib Temsirolimus 2011 Crizotinib Ruxolitinib Vemurafenib Vandetanib 2013 Afatinib Dabrafenib Trametinib 2015 Lenvatinib Alectinib Palbociclib Panobinostat Nindetanib

13 Outline of my Talk Targeted Therapy for Cancer Challenges and Costs
Another Example: Hepatitis C Approval Times for New Cancer Drugs Combination is Key – What are the Costs? Future Directions

14 The Challenges for the Global Industry
Of 4300 companies, 261 (6%) have registered a new cancer drug since 1950. Patent expirations : more than $113 Billion For every dollar lost, new revenues projected at 26 cents R&D Productivity in decline - Discovery of new cancer drugs down 50% in past 5 years 200,000 industry jobs will be shed 2009 – 2015 Average cost of a cancer drug to market: $1.1 billion - But late stage failures make real cost $ billion!

15 The Challenges for the Society (US)
Annual cancer care costs in the US are projected to rise from $ 104 billion in to $ 175 Billion in Germany (2014): € 15 Billion The number of new cases of cancer will rise from 11.3 million in 2007 to million in Germany (2014): 450,000 pts. The US spend for cancer drugs rose 400% from , largely driven by new biological agents. Generic biologics will likely be costly. The cost of drugs given in doctor‘s office rose 276% from while insurance increase was 47%. A new cancer drug is ten times more likely to be prescribed for a patient in the US as compared to Europe. The average US household budget for health care is the same as for food.

16 The Challenge for Germany
500 Cost (Billion EURO) Market Development Cancer (15) Dementia (50) 200 „NHS“ Diabetes (80) 2014 2035

17 Cost Of Approved Oncology Agents
Drug Target Indication Cost/Year Ipilimumab CTLA-4 Melanoma $ 120,000 Sipulleucel-T Cell therapy Prostate $ 90,000 Bevacizumab VEGF-A Various Nab-Paclitaxel Tubulin Pancreas $ 80,000 Lenalidomide IMID Myeloma Bortezomib Proteasome $ 60,000 Imatinib acr-abl CML $ 70,000 Ofatumumab CD-20 CLL 5-Fluorouracil TS CRC $ 300

18 The Cost-Effectiveness Plane

19

20 Outline of my Talk Targeted Therapy for Cancer Challenges and Costs
Another Example: Hepatitis C Approval Times for New Cancer Drugs Combination is Key – What are the Costs? Future Directions

21 Enter The Block Buster Hurricane Season
Hepatitis-C: Enter The Block Buster Hurricane Season Following acute infection, a chronic, often asymptomatic disease Prevalence (US): 16,000 acute, 3.2 million chronic Over years chronic infection will lead to cirrhosis (5-20%) or liver cancer (5%) No vaccine available Until recently, treatment included peg-IFN, ribavirin +/- telaprevir or boceprevir And then the pharmaco-economic barometer dropped

22 Targeted Therapy in Another Tribe: The Pharmaco-Economic Impact
Sofosbuvir (Solvaldi®, Gilead) MOA: NS5B polymerase inhibitor FDA approved in 2013 Pivotal Trial: Dual IFN-free Regimen of Sosobuvir plus Ribavirin for 24 weeks resulted in cure for 100% of treatment-naive patients Early 2014, the American Association for Study of Liver Diseases and the Infectious Diseases Society of America Jointly endorsed sofosbuvir and ribavirin +/- peg-IFN for first-line treatment of Hepatitis-C Cost: $ 84,000 ($ 1,000/pill), BUT: Benefit: 14.5 QLYS (favorable cost-utility compared to managing end stage liver failure, transplant or cancer)

23 Targeted Treatment in Another Tribe: The Perfect Storm
FDA approves combination of ledipasvir (NS5A inhibitor) and sofosbuvir (NS5B inhibitor) as first treatment for Hepatitis-C not containing IFN or ribavirin Ledipasvir to be priced at $ 94K/12 weeks vs. the cost of Sofosobuvir at $ 84K However, the possibility of ledipasvir monotherapy for 8 weeks would lower cost to $ 66K (applicable to 50% of patients) Licensing agreements quickly established to make drug available in developing countries at a fraction of cost With possibility of cure, insurances approved wider screening to detect asymptomatic patients, compounding cost projections

24 The Hepatitis-C Paradigm
Will Oncology be So “Lucky”? Cancer is more complex than a viral disease: Cancer is > 200 different diseases: many orphans in the family Multiple pathways, targets and mutations involved Treatment toxicities weigh into the cost-benefit and cost-utility calculations No accepted surrogate markers for clinical benefit Complex and confoundable clinical trial endpoints requiring large studies Combinations will be key to progress Combinations may also be as problematic as for hepatitis-C

25 Outline of my Talk Targeted Therapy for Cancer Challenges and Costs
Another Example: Hepatitis C Approval Times for New Cancer Drugs Combination is Key – What are the Costs? Future Directions

26 Clinical And Approval Times By Therapeutic Class

27 Time For Development of Oncology Drugs

28 Crizotinib: Pathway from Compound Identification to FDA Approval
Crizotinib (XALKORI®): Targeting the ALK fusion gene, a direct driver of oncogenesis Lead Com-pound identified Clinical testing begins Discovery of EML4-ALK fusion gene First clinical responses observed in ALK+ tumours Phase 3 lung cancer trial initiated ASCO plenary of expanded ALK+ cohort NEJM publication of ALK+ cohort2 NDA, PMA Sub- missions XALKORI®, FISH test approvals 2005 2006 2007 2008 2009 2010 2011 Rapid Timeline from Compound Identification, Target Discovery and Clinical Results 28 28

29 Oncology NDAs in 2014 Drug Target Indication Pembrolizumab PD-1 Melanoma Idelalisib PI3K CLL Belinostat HDAC PTCL Ceritinib ALK NSCLC Siltuximab IL-6 Castleman‘s disease Ramucirumab VEGF-R2 Gastric cancer; NSCLC But the current emerging pharmaco-economic challenges are in earlier approvals and in combinations!

30 Outline of my Talk Targeted Therapy for Cancer Challenges and Costs
Another Example: Hepatitis C Approval Times for New Cancer Drugs Combination is Key – What are the Costs? Future Directions

31 Targeted Therapy: Combination Studies
Most striking example: Malignant Melanoma

32 Metastatic Malignant Melanoma:
Immunotherapy Targets: DTIC: Alkyting agent Ipilimumab: anti-CTLA-4 Nivolumab: anti-PD-1 DTIC Ipilimumab Nivolumab Ipi + Nivo 39.7 Median OS (months) 6 12 18 24

33 Metastatic Malignant Melanoma:
TKIs DTIC Targets: Vemurafenib: B-raf Dabrafenib: B-raf/MEK1,2 Trametinib: MEK1,2 Vemurafenib Dabrafenib Trametinib Dab + Tra Not reached Median OS (months) 6 12 18 24

34 Targeted Therapy in Melanoma
Breaking the Cost Barrier with Combinations Trametinib (GSK): MEK Inhibitor approved in 2013 (V600E-positive melanoma) Dabrafenib (GSK): BRAF Inhibitor approved in 2013 (V600E-positive melanoma) Trametinib and Dabrafenib launched as monotherapy below the cost of vemurafenib at $ 8500/$ 7985 per month versus $ 9400/month In early 2014, FDA approved the agents as the first two to be found safe and effective in combination But, at a cost of $ 17,115/month

35 Outline of my Talk Targeted Therapy for Cancer Challenges and Costs
Another Example: Hepatitis C Approval Times for New Cancer Drugs Combination is Key – What are the Costs? Future Directions

36 Making Early Drug Development More Efficient to Control Research Risks and Costs
More predictable (and reproducible) non-clinical models Use of validated biomarkers for staged risk management - Proof of Mechanism (PoM) (target hit) - Proof of Principle (PoP) (effect on disease, e.g., cell death markers) - Proof of Concept (PoC) (clinical effect) Use of PK/PD to choose schedule early - Moderate normal tissue toxicities - Maximise pathway inhibition - Maintain dose intensity - Abrogate development of resistance Earlier investigation of combinations Inclusion of patients with earlier stages of disease

37 Making Late Stage Drug Development More Efficient to Control Research Risks and Costs
Risk sharing between companies Use of predictive biomarkers for patient selection - Smaller, more focused phase 3 trials - Potential need to screen many patients - Decrease late stage failures NCI Innovative Clinical Trial Designs - Identify biomarker signatures predicting response - Graduate drug/biomarker pairs to smaller, more focused phase 3 trials Explore utility of new cancer drugs in other indications and vice versa

38 Executive Summary We still do not know the optimal target for cancer treatment. Status: Approval time 7 years, costs $ 1.1 billion, success rate < 20%. Combination is key – but might be “financially toxic”. Making cancer drug development more efficient is still a challenge. Do not forget: In cancer care cost matters!


Download ppt "Cancer Drug Development in Industry:"

Similar presentations


Ads by Google